Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label attachment file name title previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1132035

	registered interest
	date	13/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Primary Care Networks
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the requirements for primary care networks to engage with the local community will be.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	264406
	answer	answer is ministerial correction date of answer 18/06/2019 answer text <p><ins class="ministerial"> <p><ins class="ministerial">Primary Care Networks (PCNs) are a new way for primary and community service organisations to work together. For PCNs to be successful they will need to work in partnership with local people and the communities they serve. Legal duties which currently apply to NHS service providers - including general practitioner practices - and commissioners around engagement and consultation will continue to be valid for PCNs.</ins></p></ins></p><p><del class="ministerial">NHS England and NHS Improvement, together with the National Institute for Health and Care Excellence, is developing a ’commercial framework’ setting out the parameters for the commercial approach for medicines in the health service in England.</del></p><p><del class="ministerial">The commercial framework will support a single, transparent, robust and integrated pricing and market access process, and is being tested with and informed through consultation with stakeholders including the Association of the British Pharmaceutical Industry.</del></p><p><del class="ministerial">In preparation for public consultation in the coming months, NHS England is actively engaging with industry trade bodies and health system partners, in the first instance, to outline progress on the development of the commercial framework. The consultation on the draft framework is anticipated to be launched in Quarter 3 2019 with consultation events to be held in Manchester and London, and implementation of the commercial framework is expected to follow.</del></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 18/06/2019 16:34:05 question first ministerially corrected 19/06/2019 08:36:30 answering member 4455 label Biography information for Seema Kennedy previous answer version 123829 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	4249 label Biography information for Anne Marie Morris

1128442

	registered interest
	date	23/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will publish the evidence (a) his Department and (b) the Department for International Trade holds on growing a market for prescribed medicinal cannabis.
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	uin	257706
	answer	answer is ministerial correction date of answer 10/06/2019 answer text <p><ins class="ministerial"> <p><ins class="ministerial">The Department for International Trade and the Department of Health and Social Care are not specifically collecting data on the growth of the market for cannabis based products for medicinal use in the United Kingdom.</ins></p><p><ins class="ministerial">However, data from the Medicines and Healthcare products Regulatory Agency (MHRA) shows growing numbers of import notifications for medicinal cannabis and the Home Office has received increased numbers of licence applications.</ins></p><p><ins class="ministerial">In addition, UK companies exporting these products and foreign companies looking to invest in the UK have full access to government support, where they have the necessary authorisations from the MHRA and Home Office and a relevant Export Licence.</ins></p></ins></p><p><del class="ministerial">An initial impact assessment was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. This can be viewed at the following link:</del></p><p><del class="ministerial"><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts" target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></del></p><p><del class="ministerial">This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of cannabis-based products for medicinal use (CBPM). This framework included potential savings in treatment costs, giving the example of patients with severe epilepsy for whom medicinal use of cannabis could reduce the frequency of seizures and reduce the number of related hospital admissions. This was an initial framework for assessing this policy and as we develop our knowledge in this area, both on the costs and the potential benefits, we can revisit and refine these assessments.</del></p><p><del class="ministerial">In the meantime, the National Institute for Health and Care Excellence (NICE) is developing clinical guidelines on the appropriate use of CBPM based on the best available evidence, and the National Institute for Health Research is funding further clinical research on this. More information is available at the following link:</del></p><p><del class="ministerial"><a href="https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf" target="_blank">https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf</a></del></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 10/06/2019 13:18:03 question first ministerially corrected 11/06/2019 11:31:21 answering member 4455 label Biography information for Seema Kennedy previous answer version 121340 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1528 label Biography information for Sir Mike Penning

1140582

	registered interest
	date	19/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when he plans to issue guidance to health professionals on the Serious Shortage Protocol.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	279389
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>A Serious Shortage Protocol is an additional tool to manage serious medication shortages and may be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.</p><p>At present we are currently working on the governance process for developing Serious Shortage Protocols, should one be required, through engagement, including with professional bodies and patient groups. Following this we will issue guidance to health professionals in due course.</p><p>The Pharmaceutical Services Negotiating Committee, the organisation who represent National Health Service community pharmacy contractors in England, have developed a briefing note to support community pharmacies, who will need to consider training and changes to their standard operating-procedures to take account of the potential new processes.</p><p>Any Serious Shortage Protocol would be developed by senior, specialist doctors and pharmacists, with input from national experts, Royal Colleges and specialist societies. If a Serious Shortage Protocol is to be authorised then there will also be engagement with the relevant patient groups, who can assist in informing patients. Pharmacists still have to use their professional judgment as to whether supplying against the protocol rather than the prescription is appropriate and provide the patient with relevant information. If they determine supply is not appropriate, then the patient should be referred back to their prescriber.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 26/07/2019 11:34:54 answering member 4455 label Biography information for Seema Kennedy previous answer version 131086 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1439 label Biography information for Norman Lamb

1140584

	registered interest
	date	19/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans the Government has provide information to patients on changes to the provision of medicines as a result of the serious shortage protocol; and if he will make a statement.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	279390
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>A Serious Shortage Protocol is an additional tool to manage serious medication shortages and may be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.</p><p>At present we are currently working on the governance process for developing Serious Shortage Protocols, should one be required, through engagement, including with professional bodies and patient groups. Following this we will issue guidance to health professionals in due course.</p><p>The Pharmaceutical Services Negotiating Committee, the organisation who represent National Health Service community pharmacy contractors in England, have developed a briefing note to support community pharmacies, who will need to consider training and changes to their standard operating-procedures to take account of the potential new processes.</p><p>Any Serious Shortage Protocol would be developed by senior, specialist doctors and pharmacists, with input from national experts, Royal Colleges and specialist societies. If a Serious Shortage Protocol is to be authorised then there will also be engagement with the relevant patient groups, who can assist in informing patients. Pharmacists still have to use their professional judgment as to whether supplying against the protocol rather than the prescription is appropriate and provide the patient with relevant information. If they determine supply is not appropriate, then the patient should be referred back to their prescriber.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 279391 question first answered 26/07/2019 11:36:12 answering member 4455 label Biography information for Seema Kennedy previous answer version 131087 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1439 label Biography information for Norman Lamb

1140585

	registered interest
	date	19/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions the Government has had with (a) patient groups and (b) professional bodies on the development of the serious shortage protocol.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	279391
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>A Serious Shortage Protocol is an additional tool to manage serious medication shortages and may be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.</p><p>At present we are currently working on the governance process for developing Serious Shortage Protocols, should one be required, through engagement, including with professional bodies and patient groups. Following this we will issue guidance to health professionals in due course.</p><p>The Pharmaceutical Services Negotiating Committee, the organisation who represent National Health Service community pharmacy contractors in England, have developed a briefing note to support community pharmacies, who will need to consider training and changes to their standard operating-procedures to take account of the potential new processes.</p><p>Any Serious Shortage Protocol would be developed by senior, specialist doctors and pharmacists, with input from national experts, Royal Colleges and specialist societies. If a Serious Shortage Protocol is to be authorised then there will also be engagement with the relevant patient groups, who can assist in informing patients. Pharmacists still have to use their professional judgment as to whether supplying against the protocol rather than the prescription is appropriate and provide the patient with relevant information. If they determine supply is not appropriate, then the patient should be referred back to their prescriber.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 279390 question first answered 26/07/2019 11:36:13 answering member 4455 label Biography information for Seema Kennedy previous answer version 131085 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1439 label Biography information for Norman Lamb

1140919

	registered interest
	date	22/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many finished consultant episodes there were with a (a) primary and (b) secondary diagnosis of HIV infection in (i) England and (ii) each region in each year since 1989.
	tabling member constituency	Leicester South
	tabling member printed	Jonathan Ashworth
	uin	280282
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>Data on HIV diagnoses are not available by hospital consultant episode, or by primary and secondary diagnosis.</p><p>Public Health England (PHE) routinely collects data on people confirmed newly diagnosed with HIV care in the United Kingdom. Data on those newly diagnosed and resident in England and each PHE centre of residence from 1981 to 2017 are available to view at the following link:</p><p><a href="https://www.gov.uk/government/statistics/hiv-annual-data-tables" target="_blank">https://www.gov.uk/government/statistics/hiv-annual-data-tables</a></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 26/07/2019 11:42:23 answering member 4455 label Biography information for Seema Kennedy previous answer version 131375 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	4244 label Biography information for Jonathan Ashworth

1140924

	registered interest
	date	22/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Orthopaedics
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to tackle the recent increase in diabetes-related amputations.
	tabling member constituency	East Londonderry
	tabling member printed	Mr Gregory Campbell
	uin	280192
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>Evidence suggests that multidisciplinary footcare teams (MDFTs) play a major role in a good diabetes footcare pathway and can significantly reduce amputations and subsequently the financial burden of diabetic foot disease.</p><p>The NHS Long Term Plan includes a commitment to “ensure that all hospitals in future provide access to MDFTs and diabetes inpatient specialist nursing teams to improve recovery and to reduce lengths of stay and future readmission rates”.</p><p>Since April 2017 NHS England has made £26 million available through the diabetes transformation funding to put in place 41 new or expanded MDFTs, reducing the risk of people with ulcers or other diabetes foot disease from having an amputation.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 26/07/2019 11:37:09 answering member 4455 label Biography information for Seema Kennedy previous answer version 131374 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1409 label Biography information for Mr Gregory Campbell

1140937

	registered interest
	date	22/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Silicosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what data his Department holds on whether there is a (a) genetic, (b) socio-economic and (c) ethnic bias to the condition of silicosis.
	tabling member constituency	High Peak
	tabling member printed	Ruth George
	uin	280411
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>Information about genetic bias in patients with silicosis is not held centrally.</p><p>The following table shows the number of finished admission episodes where there was a primary diagnosis of silicosis, as well as the ethnicity specified by the patient in each episode, over five years.</p><p><strong> </strong></p><table><tbody><tr><td colspan="2"><p>Ethnicity</p></td><td><p>2013-14</p></td><td><p>2014-15</p></td><td><p>2015-16</p></td><td><p>2016-17</p></td><td><p>2017-18</p></td></tr><tr><td><p>A</p></td><td><p>British (White)</p></td><td><p>17</p></td><td><p>20</p></td><td><p>17</p></td><td><p>11</p></td><td><p>14</p></td></tr><tr><td><p>B</p></td><td><p>Irish (White)</p></td><td><p>3</p></td><td><p>1</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>C</p></td><td><p>Any other White background</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>1</p></td><td><p>-</p></td></tr><tr><td><p>D</p></td><td><p>White and Black Caribbean (Mixed)</p></td><td><p>-</p></td><td><p>-</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1</p></td></tr><tr><td><p>H</p></td><td><p>Indian (Asian or Asian British)</p></td><td><p>1</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>J</p></td><td><p>Pakistani (Asian or Asian British)</p></td><td><p>-</p></td><td><p>1</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>M</p></td><td><p>Caribbean (Black or Black British)</p></td><td><p>2</p></td><td><p>1</p></td><td><p>-</p></td><td><p>1</p></td><td><p>-</p></td></tr><tr><td><p>N</p></td><td><p>African (Black or Black British)</p></td><td><p>-</p></td><td><p>-</p></td><td><p>2</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>S</p></td><td><p>Any other ethnic group</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>1</p></td></tr><tr><td><p>Z</p></td><td><p>Not stated</p></td><td><p>-</p></td><td><p>-</p></td><td><p>3</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>99</p></td><td><p>Unknown</p></td><td><p>-</p></td><td><p>-</p></td><td><p>4</p></td><td><p>-</p></td><td><p>2</p></td></tr><tr><td><p>Total</p></td><td><p> </p></td><td><p>23</p></td><td><p>23</p></td><td><p>27</p></td><td><p>14</p></td><td><p>18</p></td></tr><tr><td colspan="2"><p>Source: Hospital Episode Statistics (HES), NHS Digital</p></td></tr></tbody></table><p> </p><p>The following table shows the number of finished admission episodes where there was a primary diagnosis of silicosis, as well as the Index of Multiple Deprivation (IMD) decile relating to each episode, over five years.</p><p><strong> </strong></p><table><tbody><tr><td><p>IMD Decile</p></td><td><p>2013-14</p></td><td><p>2014-15</p></td><td><p>2015-16</p></td><td><p>2016-17</p></td><td><p>2017-18</p></td></tr><tr><td><p>Least deprived 10%</p></td><td><p>-</p></td><td><p>2</p></td><td><p>-</p></td><td><p>1</p></td><td><p>-</p></td></tr><tr><td><p>Less deprived 10-20%</p></td><td><p>3</p></td><td><p>2</p></td><td><p>4</p></td><td><p>1</p></td><td><p>-</p></td></tr><tr><td><p>Less deprived 20-30%</p></td><td><p>1</p></td><td><p>4</p></td><td><p>1</p></td><td><p>2</p></td><td><p>1</p></td></tr><tr><td><p>Less deprived 30-40%</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>1</p></td><td><p>3</p></td></tr><tr><td><p>Less deprived 40-50%</p></td><td><p>1</p></td><td><p>2</p></td><td><p>3</p></td><td><p>1</p></td><td><p>1</p></td></tr><tr><td><p>More deprived 40-50%</p></td><td><p>1</p></td><td><p>1</p></td><td><p>3</p></td><td><p>1</p></td><td><p>-</p></td></tr><tr><td><p>More deprived 30-40%</p></td><td><p>5</p></td><td><p>2</p></td><td><p>4</p></td><td><p>2</p></td><td><p>2</p></td></tr><tr><td><p>More deprived 20-30%</p></td><td><p>5</p></td><td><p>3</p></td><td><p>3</p></td><td><p>2</p></td><td><p>3</p></td></tr><tr><td><p>More deprived 10-20%</p></td><td><p>4</p></td><td><p>3</p></td><td><p>2</p></td><td><p>1</p></td><td><p>3</p></td></tr><tr><td><p>Most deprived 10%</p></td><td><p>2</p></td><td><p>3</p></td><td><p>6</p></td><td><p>2</p></td><td><p>5</p></td></tr><tr><td><p>Unknown</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Total</p></td><td><p>23</p></td><td><p>23</p></td><td><p>27</p></td><td><p>14</p></td><td><p>18</p></td></tr><tr><td><p>Source: HES, NHS Digital</p></td></tr></tbody></table><p> </p><p>Note:</p><table><tbody><tr><td><p>Finished admission episodes</p></td></tr><tr><td><p>A finished admission episode (FAE) is the first period of admitted patient care under one consultant within one healthcare provider. Admissions do not represent the number of patients, as a person may have more than one admission within the period.</p></td></tr><tr><td><p>IMD Decile</p></td></tr><tr><td><p>This field uses the IMD Overall Ranking to identify which one of ten groups a Super Output Area belongs to, from most deprived through to least deprived. IMD version 2010 is used from 2010-11 onwards.</p></td></tr></tbody></table><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 26/07/2019 11:41:41 answering member 4455 label Biography information for Seema Kennedy previous answer version 131371 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	4662 label Biography information for Ruth George

1129191

	registered interest
	date	03/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescription Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many prescriptions of (a) individual benzodiazepine drugs and (b) individual antidepressants were dispensed in the community in 2018.
	tabling member constituency	Bristol North West
	tabling member printed	Darren Jones
	uin	259400
	answer	answer is ministerial correction date of answer 11/06/2019 answer text <p>Information on the number of prescription items from the Prescription Cost Analysis system for benzodiazepines and antidepressants written in the United Kingdom and dispensed in the community in England, for the year 2018 can be found in the attached tables.</p><p>The data available is at prescription item level by presentation. Prescriptions are prescribed either by a paper prescription form or via an Electronic Prescription Service message. Each single item written on the form is counted as a prescription item. No information is available for those prescriptions written but not dispensed.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 11/06/2019 16:51:00 question first ministerially corrected 12/06/2019 14:34:05 answering member 4455 label Biography information for Seema Kennedy attachment 1 file name PQ259400 table formatted.docx title Prescription data benzodiazipines & antidepressant previous answer version 122124 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	4621 label Biography information for Darren Jones

1138888

	registered interest
	date	15/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Sickle Cell Diseases: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 23 May 2019 to Question 256313 on Sickle Cell Diseases, which services (a) NHS England, (b) clinical commissioning groups and (c) other public bodies commission for people with sickle cell disease; and what the per capita annual cost is of providing each of those services.
	tabling member constituency	Kingston upon Hull North
	tabling member printed	Diana Johnson
	uin	277137
	answer	answer is ministerial correction date of answer 19/07/2019 answer text <p>NHS England commissions specialised services for people living with sickle cell disease. These services are part of the specialised haemoglobinopathy services commissioned by NHS England across the country. NHS England spends over £60 million on sickle cell disease within these services annually - £60.4 million in 2017/18. Information about the services provided by individual clinical commissioning groups or other public bodies is not collected or held centrally.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 19/07/2019 09:46:21 answering member 4455 label Biography information for Seema Kennedy previous answer version 129855 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1533 label Biography information for Dame Diana Johnson